← board
APMD
ApnimedRevenue
pre-revenue
Liquidity
—
Runway
—
Shares 1y
—
Pipeline stages · 1 programs
Aroxybutynin and Atomoxetine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06-30 | Phase 3 | Aroxybutynin and Atomoxetine | OSA | — | enrolling by invitation |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: —
- 2026-07-10S-1shelf_registration
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-21Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
- 2026-07-15FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea - NeurologyLive
- 2026-07-15Braveheart, Attovia, Apnimed join gene therapy firm Scribe in July IPO rush - Seeking Alpha
- 2026-07-15FDA Accepts NDA for Apnimed Sleep Apnea Pill - respiratory-therapy.com
- 2026-07-14Apnimed's Oral OSA Therapy Clears FDA Hurdle - AllSci
- 2026-07-14Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA) - PR Newswire
- 2026-07-13Agenus surges on study pivot; Apnimed lines up an IPO - Yahoo Finance
- 2026-07-13Apnimed files for IPO as FDA reviews its sleep apnea drug - Endpoints News
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.